HCA Healthcare, Inc. (NYSE:HCA) Shares Sold by Cigna Investments Inc. New

Cigna Investments Inc. New decreased its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 1.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,928 shares of the company’s stock after selling 33 shares during the period. Cigna Investments Inc. New’s holdings in HCA Healthcare were worth $579,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in HCA. Atomi Financial Group Inc. acquired a new position in shares of HCA Healthcare in the third quarter worth about $233,000. Valeo Financial Advisors LLC boosted its holdings in shares of HCA Healthcare by 11.5% in the third quarter. Valeo Financial Advisors LLC now owns 1,060 shares of the company’s stock worth $431,000 after buying an additional 109 shares during the period. McGlone Suttner Wealth Management Inc. acquired a new position in shares of HCA Healthcare in the third quarter worth about $235,000. Sound Income Strategies LLC boosted its holdings in shares of HCA Healthcare by 82.2% during the third quarter. Sound Income Strategies LLC now owns 634 shares of the company’s stock worth $258,000 after purchasing an additional 286 shares during the period. Finally, Redhawk Wealth Advisors Inc. acquired a new stake in shares of HCA Healthcare during the third quarter worth approximately $926,000. Institutional investors own 62.73% of the company’s stock.

Insider Activity

In other HCA Healthcare news, SVP Phillip G. Billington sold 3,897 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the sale, the senior vice president now owns 52,702 shares in the company, valued at $18,445,700. This represents a 6.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the sale, the insider now owns 6,843 shares in the company, valued at $2,415,579. This represents a 29.76 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

HCA Healthcare Stock Down 1.2 %

Shares of HCA Healthcare stock opened at $318.28 on Tuesday. The company has a quick ratio of 0.97, a current ratio of 1.08 and a debt-to-equity ratio of 69.07. HCA Healthcare, Inc. has a 12 month low of $289.98 and a 12 month high of $417.14. The business has a fifty day simple moving average of $313.75 and a 200 day simple moving average of $353.51. The stock has a market cap of $80.62 billion, a PE ratio of 14.49, a price-to-earnings-growth ratio of 1.11 and a beta of 1.64.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Friday, January 24th. The company reported $6.22 EPS for the quarter, topping analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. During the same quarter in the previous year, the firm earned $5.90 earnings per share. Research analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 17th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.90%. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.66. The ex-dividend date of this dividend is Monday, March 17th. HCA Healthcare’s payout ratio is presently 12.02%.

Wall Street Analysts Forecast Growth

HCA has been the topic of several recent research reports. Morgan Stanley cut their price objective on shares of HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Royal Bank of Canada cut their price objective on shares of HCA Healthcare from $405.00 to $384.00 and set an “outperform” rating on the stock in a research report on Monday, January 27th. Truist Financial reduced their price objective on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a research note on Monday, January 6th. TD Cowen cut their target price on shares of HCA Healthcare from $450.00 to $440.00 and set a “buy” rating for the company in a research report on Monday, October 28th. Finally, Barclays decreased their target price on HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $385.67.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.